These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 31234673)

  • 1. A review of kallikrein inhibitor lanadelumab in hereditary angioedema.
    Hwang G; Johri A; Ng S; Craig T
    Immunotherapy; 2019 Aug; 11(11):937-944. PubMed ID: 31234673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lanadelumab for the prevention of attacks in hereditary angioedema.
    Valerieva A; Senter R; Wu MA; Zanichelli A; Cicardi M
    Expert Rev Clin Immunol; 2019 Dec; 15(12):1239-1248. PubMed ID: 31721602
    [No Abstract]   [Full Text] [Related]  

  • 3. Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies.
    Busse PJ; Farkas H; Banerji A; Lumry WR; Longhurst HJ; Sexton DJ; Riedl MA
    BioDrugs; 2019 Feb; 33(1):33-43. PubMed ID: 30539362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis.
    Banerji A; Busse P; Shennak M; Lumry W; Davis-Lorton M; Wedner HJ; Jacobs J; Baker J; Bernstein JA; Lockey R; Li HH; Craig T; Cicardi M; Riedl M; Al-Ghazawi A; Soo C; Iarrobino R; Sexton DJ; TenHoor C; Kenniston JA; Faucette R; Still JG; Kushner H; Mensah R; Stevens C; Biedenkapp JC; Chyung Y; Adelman B
    N Engl J Med; 2017 Feb; 376(8):717-728. PubMed ID: 28225674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lanadelumab to treat hereditary angioedema.
    Wedi B
    Drugs Today (Barc); 2019 Jul; 55(7):439-448. PubMed ID: 31347612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, Pharmacodynamics, and Exposure-Response of Lanadelumab for Hereditary Angioedema.
    Wang Y; Marier JF; Kassir N; Chang C; Martin P
    Clin Transl Sci; 2020 Nov; 13(6):1208-1216. PubMed ID: 32407574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lanadelumab: First Global Approval.
    Syed YY
    Drugs; 2018 Oct; 78(15):1633-1637. PubMed ID: 30267321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lanadelumab for the treatment of hereditary angioedema.
    Wu MA
    Expert Opin Biol Ther; 2019 Dec; 19(12):1233-1245. PubMed ID: 31657963
    [No Abstract]   [Full Text] [Related]  

  • 9. Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy.
    Bova M; Valerieva A; Wu MA; Senter R; Perego F
    Drug Des Devel Ther; 2019; 13():3635-3646. PubMed ID: 31695331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension.
    Riedl MA; Bernstein JA; Craig T; Banerji A; Magerl M; Cicardi M; Longhurst HJ; Shennak MM; Yang WH; Schranz J; Baptista J; Busse PJ
    Clin Transl Allergy; 2017; 7():36. PubMed ID: 29043014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The bradykinin-forming cascade and its role in hereditary angioedema.
    Kaplan AP; Joseph K
    Ann Allergy Asthma Immunol; 2010 Mar; 104(3):193-204. PubMed ID: 20377108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological therapy in hereditary angioedema: transformation of a rare disease.
    Longhurst H; Farkas H
    Expert Opin Biol Ther; 2020 May; 20(5):493-501. PubMed ID: 31994957
    [No Abstract]   [Full Text] [Related]  

  • 13. Bradykinin-mediated diseases.
    Kaplan AP
    Chem Immunol Allergy; 2014; 100():140-7. PubMed ID: 24925394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indirect Comparison of Lanadelumab and Intravenous C1-INH Using Data from the HELP and CHANGE Studies: Bayesian and Frequentist Analyses.
    Mendivil J; Malmenäs M; Haeussler K; Hunger M; Jain G; Devercelli G
    Drugs R D; 2021 Mar; 21(1):113-121. PubMed ID: 33646565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lanadelumab: A Review in Hereditary Angioedema.
    Syed YY
    Drugs; 2019 Nov; 79(16):1777-1784. PubMed ID: 31560114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hereditary angioedema due to C1-esterase inhibitor deficiency : novel approaches].
    Stehlin F; Ribi C
    Rev Med Suisse; 2020 Apr; 16(689):675-678. PubMed ID: 32270933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic monoclonal antibodies with a focus on hereditary angioedema.
    Zuraw BL; Maurer M; Sexton DJ; Cicardi M
    Allergol Int; 2023 Jan; 72(1):54-62. PubMed ID: 35787344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Experiencia inicial de Lanadelumab en una paciente mexicana con angioedema hereditario tipo I].
    García-Rosas C; López-Tiro JJ; Contreras-Contreras A; Ruiz-Peñaloza M; Ortiz-Monteón ZE
    Rev Alerg Mex; 2023 Sep; 70(4):194. PubMed ID: 37933935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report.
    Gidaro A; La Cava L; Donadoni M; Popescu Janu V; Cogliati C; Brucato AL; Zanichelli A; Cancian M; Bizzi E
    Front Immunol; 2024; 15():1472390. PubMed ID: 39399485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Decade of Change: Recent Developments in Pharmacotherapy of Hereditary Angioedema (HAE).
    Bork K
    Clin Rev Allergy Immunol; 2016 Oct; 51(2):183-92. PubMed ID: 27207174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.